United Therapeutics Form 144: Insider files sale notice

United Therapeutics Corporation submitted a Form 144 notice of proposed sale of securities by an insider.

Rhea-AI Filing Summary

United Therapeutics Corporation submitted a Form 144 notice of proposed sale of securities by an insider. The filing lists a planned stock option exercise and proposed sale of 20 common shares on 03/04/2026 for cash to the issuer. The filing also discloses three recent open-market sales by Christopher Causey: $520,000 for 1,000 shares on 02/25/2026, $510,000 for 1,000 shares on 01/06/2026, and $500,014.60 for 1,000 shares on 01/02/2026.

Insights

Insider Transactions Analyst

TL;DR: Routine insider disposition notice showing small recent sales and a planned option exercise for 20 shares.

The filing records a proposed stock option exercise tied to 03/04/2026 for 20 common shares, with the method shown as cash and the counterparty listed as the issuer. This indicates proceeds flow to the company upon exercise.

Separately, the excerpt lists three completed sales by Christopher Causey totaling 3,000 shares across 01/02/2026, 01/06/2026, and 02/25/2026 with the specific proceeds shown. These entries are typical reporting of insider liquidity events; no further material context or qualifier is provided in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does United Therapeutics (UTHR) Form 144 disclose about planned sales?

The Form 144 shows a planned stock option exercise and sale of 20 common shares on 03/04/2026. The method is listed as cash with the counterparty shown as the issuer, indicating proceeds to the company.

How many shares did Christopher Causey sell recently according to the filing?

The excerpt discloses three sales by Christopher Causey totaling 3,000 common shares across 01/02/2026, 01/06/2026, and 02/25/2026, with proceeds of $500,014.60, $510,000, and $520,000, respectively.

Who receives the cash from the planned 20-share stock option exercise?

The filing entry lists the recipient as the issuer and the sale method as cash, indicating the company receives the exercise proceeds for the 20 common shares planned on 03/04/2026.

Does the Form 144 excerpt show material changes to company ownership or control?

No material change to ownership or control is shown in the excerpt. The filing reports routine insider sales and a small 20-share option exercise; these items are customary liquidity events and are not presented as company-changing actions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001237334
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	UNITED THERAPEUTICS CORPORATION
SEC File Number	000-26301
Address of Issuer	1000 SPRING STREET SILVER SPRING MARYLAND 20910
Phone	(301) 608-9292
Name of Person for Whose Account the Securities are To Be Sold	CHRISTOPHER CAUSEY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20	9803.37	43827686	03/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/04/2026	Stock Option Exercise	Issuer			20	03/04/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHRISTOPHER CAUSEY 1000 SPRING STREET SILVER SPRING MD 20910	Common	02/25/2026	1000	520000.00
CHRISTOPHER CAUSEY 1000 SPRING STREET SILVER SPRING MD 20910	Common	01/06/2026	1000	510000.00
CHRISTOPHER CAUSEY 1000 SPRING STREET SILVER SPRING MD 20910	Common	01/02/2026	1000	500014.60

144: Remarks and Signature

Remarks
Date of Notice	03/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/30/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christopher Causey
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)